Tools for Managing Potential Adverse Events and Avoiding Drug-Drug Interactions
This series of three activities or initiatives will evaluate clinical guidelines for the use of opioids, including the REMS requirements, and their impact on the management of chronic pain. This initiative will also evaluate recommended opioid risk-reduction strategies HCPs can use to detect opioid misuse in a timely manner. Finally, the initiative will identify communication strategies HCPs can use to improve their relationships with their patients to ensure optimal patient outcomes and reduce the risk of opioid misuse and abuse.
The target audience includes all clinicians registered with the DEA, eligible to prescribe schedule 2 or 3 drugs that have written at least one ER/LA opioid prescription in the past year, including Primary Care (Family Practice and Internal Medicine), Anesthesiology (including Pain Management), Oncology, Neurology, Orthopedics, PM&R and Palliative Care physicians, physician assistants and nurse practitioners. Pharmacists would also benefit from this education.
Upon completion of this activity, participants will be able to:
- Identify potential adverse events in patients on ER/LA opioid therapy
- Mitigate drug-drug interactions with patients on ER/LA opioid therapy
|Michael A. Ashburn, MD, MPH, MBA|
Professor of Anesthesiology and Critical Care
Director, Pain Medicine and Palliative Care
Hospital of the University of Pennsylvania
Charles Argoff, MD
It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) and Dannemiller that any person who is in a position to control the content of a CME/CE activity must disclose all relevant financial relationships they have with a commercial interest.
The faculty reported the following financial relationships that they or their significant other have with commericial interests:
|Name of Faculty or Presenter||Relationship Identified With:|
|Perry G. Fine, MD||Consultant/Advisor for Kaleo Pharma, Magellan Health, Pfizer Inc., and Zogenix Inc.|
|Michael A. Ashburn MD, MPH, MBA|
Research Grant: AstraZeneca, Dynamic Clinical Systems, GW Pharma, Medtronic Inc.Consultant Advisor: Becton Dickinson, Cubist, Independence Blue Cross, Maruishi Pharmaceutical Co. Ltd., Stealth Peptides, Teva Pharmaceutical Industries Ltd, the US Department of Justice, and Vantia Ltd.
|Charles Argoff, MD||Consultant/Advisor: Mallinckrodt Pharmaceuticals, Pfizer Inc., Purdue Pharma LP, Teva Pharmaceutical Industries Ltd., and Zogenix Inc.|
Non-faculty: Maunak Rana, MD, medical writer; Bernard M. Abrams, MD, Dannemiller Medical Director and content reviewer; Sandy Breslow, Richard A. DeVito Jr., Brynne Hunter, and Michelle Montgomery, Elsevier, Dannemiller and Journal of Opioid Management staff hereby state that they or their significant other do not have any financial relationships with commercial interests.
This activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.
Co-provided by the Elsevier Office of Continuing Medical Education and Dannemiller.
Course Open Date: March 27, 2015 | Course Expiration Date: September 19, 2016
CME Credit (Physicians)
This activity has been planned and implemented with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through co-providership of the Elsevier Office of Continuing Medical Education and Dammiiller. The Elsevier Office of CME is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Credit (Nurse Practitioners)
Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education . Provider Number 090419. This program was is accredited for 0.5 contact hours.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, Dannemiller, Inc. and ER/LA Opioid Analgesic REMS Program Companies do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation:
- In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and disclosures at the beginning of this activity.
- Complete the pre-activity test.
- Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation. Once you successfully complete the post-test (score of 70% or higher) and activity evaluation, your Statement of Credit will be made available immediately.
- Click on View Certificate and print the Statement of Credit for your records.
- 0.50 AANP
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician